This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Frank Fund Finds Deals in Drug Stocks

NEW YORK ( TheStreet) -- Brian Frank, manager of the Frank Value Fund (FRNKX), says fears about government regulation of health care have driven drug stocks down to bargain prices.

The $2 million fund has risen 51% during the past year, better than 83% of its Morningstar (MORN) mid-cap blend peers. It has gained 4.3% annually, on average, during the past five years, outperforming two-thirds of competing funds.

Welcome to TheStreet's Fund Manager Five Spot, where America's top mutual fund managers give their best stock picks in five fast and furious questions.

Are you a bull or bear?

Frank: I am extremely bullish on our portfolio, not necessarily the market as a whole. I think too many investors base their confidence on the economic outlook instead of the individual valuations of their holdings. For example, in 2009, long before there was any sign of an economic recovery, our portfolio enjoyed an incredible rally. This was because our stocks were cheap. Now, while the outlook for the U.S. is cloudy, there are still phenomenal bargains in companies that will outperform the recovery, if you know where to look.

What is your top stock pick?

Frank: Our top pick is WellCare Health Plans (WCG - Get Report). This is a small health care company that went through some big problems, but now all their issues are resolved. It's a sub-$40 stock with $30 of cash per share that churns out $5 per year in free cash flow. Of course, when owning health care you must be aware of government regulation, but we think WellCare will actually benefit from the government forcing people into the system.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MON $91.65 0.00%
WU $19.01 0.00%
WCG $94.89 0.00%
AAPL $94.19 0.00%
FB $118.06 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs